Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's R&D Outsourcing Market Reaches $315 Million, Expected To Maintain High Growth Through 2016

This article was originally published in The Pink Sheet Daily

Executive Summary

IPO for ShangPharma, China's second-largest CRO after the leading WuXi PharmaTech, debuted Oct. 19.

You may also be interested in...



Asia Spotlight: China's Top Drug Distributors Are Soaring

On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.

Deals Of The Week: Sanofi-Aventis/Stanford, Ariad/ReGenX, Baxter/Prism

Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.

China Releases New Drug GMPs; Domestic Consolidation Expected

SHANGHAI – China’s State FDA released its long-awaited good manufacturing practice guidelines for pharmaceutical products Feb. 12.

Topics

UsernamePublicRestriction

Register

PS071370

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel